PCSK9 and familial hypercholesterolemia: PCSK9 inhibitors have been tested for CV risk relief in two major trials: the “Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER)” study of evolocumab and the “Safety and Tolerability of Alirocumab in High Cardiovascular Risk Patients with Hypercholesterolemia Not Adequately Controlled with Their Lipid Modifying Therapy (ODYSSEY)” study of alirocumab.